Literature DB >> 3282850

The treatment of gastric ulcer with antisecretory drugs. Relationship of pharmacological effect to healing rates.

C W Howden1, D B Jones, K E Peace, D W Burget, R H Hunt.   

Abstract

Published clinical trials (N = 56) of antisecretory drugs in the treatment of benign gastric ulcer were reviewed. Composite healing rates for various drug regimens were calculated using a method previously described for duodenal ulcer. Healing rates were compared with data on suppression of intragastric acidity to see if any relationship was evident. No significant correlations between the two existed, unless placebo data were included in the analysis. Correlations were stronger with suppression of total 24-hr rather than nocturnal acidity. Using Williams' method for assessing trends, it was found that an increase in antisecretory effect is not associated with a concomitant increase in healing rates. Duration of medical treatment is the single most important factor in healing of benign gastric ulcer; healing rates for all drug regimens and placebo show a consistent increase with prolongation of treatment.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3282850     DOI: 10.1007/bf01798367

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  20 in total

1.  BASAL AND HISTALOG-STIMULATED GASTRIC SECRETION IN CONTROL SUBJECTS AND IN PATIENTS WITH PEPTIC ULCER OR GASTRIC CANCER.

Authors:  M I GROSSMAN; J B KIRSNER; I E GILLESPIE
Journal:  Gastroenterology       Date:  1963-07       Impact factor: 22.682

2.  A double-blind gastroscopic study of a bismuth-peptide complex in gastric ulceration.

Authors:  M G Moshal
Journal:  S Afr Med J       Date:  1974-08-10

3.  A test for differences between treatment means when several dose levels are compared with a zero dose control.

Authors:  D A Williams
Journal:  Biometrics       Date:  1971-03       Impact factor: 2.571

4.  Acid suppression in duodenal ulcer: a meta-analysis to define optimal dosing with antisecretory drugs.

Authors:  D B Jones; C W Howden; D W Burget; G D Kerr; R H Hunt
Journal:  Gut       Date:  1987-09       Impact factor: 23.059

5.  Comparative effects of two cimetidine regimens on 24-hour intragastric acidity in patients with asymptomatic duodenal ulcer.

Authors:  V Mahachai; K Walker; F Jamali; H Navert; D Cook; A Symes; A B Thomson
Journal:  Clin Ther       Date:  1984       Impact factor: 3.393

6.  Single nocturnal dose of an H2 receptor antagonist for the treatment of duodenal ulcer.

Authors:  T Gledhill; O M Howard; M Buck; A Paul; R H Hunt
Journal:  Gut       Date:  1983-10       Impact factor: 23.059

7.  [Ranitidine and transmural potential difference. Results with sodium taurocholate (author's transl)].

Authors:  P Müller; N Fischer; H Kather; B Simon; H G Dammann
Journal:  Dtsch Med Wochenschr       Date:  1981-11-20       Impact factor: 0.628

8.  Effects of cimetidine on the healing and recurrence of duodenal ulcers and gastric ulcers.

Authors:  M Tatsuta; H Iishi; S Okuda
Journal:  Gut       Date:  1986-10       Impact factor: 23.059

9.  Prostaglandin and cimetidine inhibit the formation of ulcers produced by parenteral salicylates.

Authors:  G L Kauffman; M I Grossman
Journal:  Gastroenterology       Date:  1978-12       Impact factor: 22.682

10.  Healing of benign gastric ulcer: comparison of cimetidine and placebo in the United States.

Authors:  D Y Graham; K Akdamar; W P Dyck; E Englert; R G Strickland; J L Achord; A A Belsito; Z R Vlahcevic; R N Kornfield; W B Long
Journal:  Ann Intern Med       Date:  1985-05       Impact factor: 25.391

View more
  18 in total

1.  Omeprazole in gastric and duodenal ulcers.

Authors:  V Savarino; G S Mela; G Celle
Journal:  Gut       Date:  1991-06       Impact factor: 23.059

Review 2.  What is potent acid inhibition, and how can it be achieved?

Authors:  Xavier Calvet; Fernando Gomollón
Journal:  Drugs       Date:  2005       Impact factor: 9.546

3.  A matched case-control study of a novel Acid-pump antagonist and proton-pump inhibitor for the treatment of iatrogenic ulcers caused by endoscopic submucosal dissection.

Authors:  Yong Gil Kim; Byung-Ik Jang; Tae Nyeun Kim
Journal:  Gut Liver       Date:  2010-03-25       Impact factor: 4.519

4.  Predictable prolonged suppression of gastric acidity with a novel proton pump inhibitor, AGN 201904-Z.

Authors:  R H Hunt; D Armstrong; M Yaghoobi; C James; Y Chen; J Leonard; J M Shin; E Lee; D Tang-Liu; G Sachs
Journal:  Aliment Pharmacol Ther       Date:  2008-04-25       Impact factor: 8.171

5.  Maintenance treatment with H2 receptor antagonists in patients with peptic ulcer disease: rarely justified in terms of cost or patient benefit.

Authors:  C W Howden
Journal:  BMJ       Date:  1988-11-26

6.  Ulcer heterogeneity: further arguments for a range of antisecretory treatment.

Authors:  V Savarino; P Zentilin; G Celle; G S Mela
Journal:  Dig Dis Sci       Date:  1990-07       Impact factor: 3.199

7.  Healing of gastric body ulcer with gastroprotective versus antisecretory treatment.

Authors:  M Jablonská
Journal:  Dig Dis Sci       Date:  1995-09       Impact factor: 3.199

Review 8.  Prescribing policy for antiulcer treatment in the elderly.

Authors:  G Bianchi Porro; M Lazzaroni
Journal:  Drugs Aging       Date:  1993 Jul-Aug       Impact factor: 3.923

Review 9.  Proton pump inhibitors: do differences in pharmacokinetics translate into differences in clinical outcomes?

Authors:  Kwong Ming Fock; Tiing Leong Ang; Lean Choo Bee; Edmund Jon Deon Lee
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

Review 10.  Histamine H2-receptor antagonists in peptic ulcer disease. Efficacy in healing peptic ulcers.

Authors:  M Deakin; J G Williams
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.